Oric Pharmaceuticals, Inc. Stock Price, News & Analysis

ORIC Pharmaceuticals, a clinical stage oncology company, will participate in two upcoming investor conferences. The Jefferies London Health Conference is scheduled for November 18, 2021, at 8:00 a.m. GMT, followed by the Evercore ISI 4th Annual HealthconX Conference on December 2, 2021, at 3:55 p.m. ET. Both events will feature virtual fireside chats available on their website. ORIC is focused on developing cancer treatments targeting therapeutic resistance, with lead candidate ORIC-101 currently in Phase 1b trials.

ORIC Pharmaceuticals (Nasdaq: ORIC) announced the appointment of Dr. Angie You to its board of directors, effective immediately. Dr. You, the current CEO of Amunix Pharmaceuticals, brings extensive experience in venture capital and business development, which ORIC believes will strengthen its leadership as it advances its oncology pipeline. Concurrently, Carl L. Gordon, Ph.D., resigned from the board. ORIC is focused on developing innovative cancer therapies, with lead candidate ORIC-101 currently in Phase 1b trials targeting therapeutic resistance in solid tumors.

ORIC Pharmaceuticals reported financial results for Q3 2021, highlighting a cash position of $296.5 million expected to fund operations into 2024. Initial clinical data from the Phase 1b trial of ORIC-101 in combination with enzalutamide showed a safe profile and preliminary antitumor activity in metastatic prostate cancer. The company also submitted a CTA for ORIC-114 and plans to initiate a Phase 1 trial for ORIC-533 in multiple myeloma. R&D expenses rose to $12.9 million, reflecting increased efforts on product candidates.

ORIC Pharmaceuticals (Nasdaq: ORIC) announced significant advancements regarding ORIC-533, a potent CD73 inhibitor, expected to begin Phase 1 trials in patients with multiple myeloma in 4Q 2021. A preclinical study presented at the ASH Annual Meeting revealed that CD73 inhibition effectively reversed immune suppression and enhanced T-cell activity against tumor cells in relapsed or refractory multiple myeloma patients. The findings highlight the potential of ORIC-533 to improve cancer treatments by overcoming therapeutic resistance.

ORIC Pharmaceuticals has announced initial data from a Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide for metastatic prostate cancer. The combination was well tolerated, with adverse events aligning with enzalutamide alone. ORIC-101 showed effective GR suppression and maintained target plasma concentrations without drug-drug interaction. Notably, in patients with moderate to high GR expression, there’s evidence of extended treatment duration. ORIC-114 demonstrated compelling preclinical activity in HER2-positive breast cancer.

ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical-stage oncology company, will present three posters at the AACR-NCI-EORTC Virtual Conference from October 7-10, 2021. These presentations will cover key findings from their Phase 1b studies involving ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide for patients with metastatic prostate cancer, and the preclinical results of ORIC-114, an irreversible kinase inhibitor for HER2-positive breast cancer. A conference call to discuss the data will be held on October 7 at 9:00 a.m. ET.

ORIC Pharmaceuticals (Nasdaq: ORIC) has announced that the FDA has cleared its IND application for ORIC-533, a CD73 inhibitor, to proceed into a first-in-human clinical trial. This trial will evaluate ORIC-533 as a standalone treatment for a tumor type not previously investigated with other CD73 inhibitors. Preclinical studies show ORIC-533 has higher potency and efficacy in blocking adenosine-driven immunosuppression compared to current alternatives. The first patient is expected to be enrolled in Q4 2021. ORIC plans additional IND filings for other product candidates in the same quarter.

ORIC Pharmaceuticals will participate in several investor conferences in September 2021. Key events include a panel on targeted oncology at Citi’s 16th Annual BioPharma Virtual Conference on September 10, a company overview at the H.C. Wainwright Conference on September 13, and a fireside chat at the Oppenheimer Summit on September 22. Webcasts will be accessible on the company’s website for 90 days post-event. ORIC is developing innovative oncology treatments, including ORIC-101, targeting resistance mechanisms in cancer therapy.

ORIC Pharmaceuticals announced the appointment of Steven L. Hoerter to its Board of Directors, a move aimed at enhancing its oncology-focused strategy. Hoerter, with over 25 years of experience in the pharmaceutical industry, has previously held significant roles at companies like Genentech and Agios. His addition is expected to provide valuable guidance as ORIC advances its four oncology product candidates, including ORIC-101, which targets therapeutic resistance mechanisms in cancer. Concurrently, Peter Svennilson resigned from the board as part of a planned reduction in commitments.